BrainEver
BrainEver is a French privately-held biotech founded in 2015, developing therapeutics for neurodegenerative disorders. Led by CEO Bernard Gilly and CSO/co-founder Alain Prochiantz, the pre-clinical/clinical-stage company is funded by the European Innovation Council, iBionext, Critical Path Ventures, and Relyens.
- Company typePrivate
- Founded2015
- HeadquartersSaint-antoine, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BrainEver does
BrainEver is a privately-held French biotechnology company founded in 2015 that operates as a medical research agency developing therapeutics for neurodegenerative disorders. Headquartered in Saint-Antoine, France, the company employs 11–50 staff and is led by founder and CEO Bernard Gilly (a serial biotech entrepreneur associated with venture builder iBionext), co-founder and Chief Scientific Officer Alain Prochiantz (a recognized neuroscientist whose academic work underpins the company's morphogen-based biology platform), Chief Medical Officer Anne Bousseau, Chief Technical & Manufacturing Officer Hubert Mechain, and Chief Project Officer Claire Friedel. BrainEver's mission is to translate proprietary CNS neuroscience research into disease-modifying drug candidates targeting neurodegenerative conditions, with the leadership structure (dedicated CMO, CTO/Manufacturing, and CPO functions) indicating an orientation toward clinical-stage execution rather than discovery-only operation.
The company's scientific platform centers on morphogen signaling and CNS pharmacology, built on co-founder Alain Prochiantz's foundational academic research into morphogen pathways and brain development. Specific pipeline assets, molecular targets, and clinical-stage progression are not disclosed in the available data, and no commercial products, licensing arrangements, or partnerships beyond investor relationships have been announced. The integration of manufacturing and project management into the executive team suggests in-house process development and disciplined program management typical of a development-stage CNS biotech.
BrainEver's business model is research-driven and pre-commercial. Pricing, customer-facing operations, and revenue mechanics are not disclosed; the company is funded almost entirely through equity and non-dilutive capital from European life-sciences investors. To date, BrainEver has raised approximately €36M cumulatively across three rounds: February 2018 (iBionext-led), March 2022 (~$2.75M, European Innovation Council-led), and July 2025 (~$38.8M / ~€33M Series 2, EIC-led with co-investment from Critical Path Ventures, iBionext, and Relyens). The EIC's repeated lead-investor role and Relyens' strategic participation as a healthcare mutual insurer point to a long-term EU-centric development pathway with potential payor-aligned commercialization optionality.
BrainEver firmographics
Firmographics- Name
- BrainEver
- Website
- https://brainever.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BrainEver is a French privately-held biotech founded in 2015, developing therapeutics for neurodegenerative disorders. Led by CEO Bernard Gilly and CSO/co-founder Alain Prochiantz, the pre-clinical/clinical-stage company is funded by the European Innovation Council, iBionext, Critical Path Ventures, and Relyens.
- Ownership category
- akta.pro rank
BrainEver industry classification
Industry- Product category
- Biopharmaceuticals / Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where BrainEver is headquartered
LocationHeadquarters
- HQ city
- Saint-antoine
- HQ country
- France
- HQ region
- Europe
Markets served
BrainEver business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Others
BrainEver product offering
Product offeringCore offering
BrainEver is a French biotech research organization focused on discovering and developing therapeutics for neurodegenerative disorders of the central nervous system. The company operates as a drug discovery agency, advancing preclinical research programs targeting brain diseases, with the intent of producing disease-modifying drug candidates that can be progressed through development or partnered with larger pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Neurodegenerative disease drug discovery programs
Companies that use BrainEver
Customer profileIdeal customer profiles1 record
BrainEver technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BrainEver partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights4 records
BrainEver competitors and assessment
Company assessmentDirect peers
- Denali Therapeutics: Clinical-stage US biotech developing therapeutics for neurodegenerative diseases, with a broad pipeline across Parkinson's, Alzheimer's, and ALS. Highly comparable to BrainEver in target indication space and modality ambition, though Denali is significantly larger and more advanced.
- Voyager Therapeutics: Clinical-stage biotech developing gene therapy-based treatments for severe CNS diseases including Parkinson's, Huntington's, and ALS. Comparable to BrainEver in CNS modality ambition and neurodegenerative disease focus, though at a more advanced clinical stage.
- Prevail Therapeutics: Gene therapy company focused on neurodegenerative diseases (Parkinson's, frontotemporal dementia, lysosomal disorders) that was acquired by Eli Lilly. Comparable to BrainEver in CNS modality and neurodegenerative indications, and a useful data point on potential exit pathways for CNS biotechs.
- Passage Bio: Clinical-stage biotech developing gene therapies for rare monogenic CNS diseases. Comparable to BrainEver in CNS focus and gene therapy/biologics modality, with similar stage and partnership-dependent business model.
Emerging players
- Axoltis Pharma: French early-stage biotech developing therapeutics for neurodegenerative diseases, with a leadership profile similar to BrainEver's CNS-focused French biotech archetype. Closely comparable in geography, stage, and indication focus.
- Affiris: Austrian biotech developing immunotherapies targeting neurodegenerative diseases, particularly Parkinson's and Alzheimer's. Comparable to BrainEver in indication focus and early-stage profile, with a different therapeutic modality.
Broad incumbents
- uniQure: Established gene therapy company with CNS pipeline assets including programs in Huntington's disease. Comparable to BrainEver in CNS modality ambition, though uniQure is more mature and platform-broad.
- Biogen: Major biopharmaceutical company with one of the largest neurodegenerative pipelines globally, including marketed and clinical-stage assets in Alzheimer's, ALS, and Parkinson's. Sets the competitive benchmark BrainEver must measure against for any CNS indication and is the most likely acquirer or partner.
- Eisai: Major Japanese pharma with a leading commercial and pipeline position in Alzheimer's and other neurodegenerative diseases. Comparable as a competitive backdrop in BrainEver's primary indications and as a likely strategic partner for any late-stage CNS asset.
Regional players
- Theranexus: French clinical-stage biotech developing drug candidates for CNS disorders. Comparable to BrainEver in geography, CNS focus, and early-stage profile, and useful as a regional benchmark for French CNS biotech financing and partnership dynamics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
BrainEver social profiles
Digital presenceBrainEver financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainEver leadership team
Management profileNumber of profiles
Profiles5 records
BrainEver funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainEver M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainEver
What does BrainEver do?
BrainEver is a French biotech research organization focused on discovering and developing therapeutics for neurodegenerative disorders of the central nervous system. The company operates as a drug discovery agency, advancing preclinical research programs targeting brain diseases, with the intent of producing disease-modifying drug candidates that can be progressed through development or partnered with larger pharmaceutical companies.
Is BrainEver a public or private company?
BrainEver is a private company. It is classified as venture growth investor backed and is currently operating.
When was BrainEver founded?
BrainEver was founded in 2015. It employs 11 to 50 people.
Where is BrainEver based?
BrainEver is headquartered in Saint-antoine, France, in the Europe region.
Who are BrainEver's main competitors?
Direct peers on record are Denali Therapeutics, Voyager Therapeutics, Prevail Therapeutics and Passage Bio. Emerging players are Axoltis Pharma and Affiris. Broad incumbents are uniQure, Biogen and Eisai. Theranexus is listed as a regional player.
Does BrainEver have an API?
No public API is recorded for BrainEver.
What industry is BrainEver in?
BrainEver's product category is Biopharmaceuticals / Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.